E-ISSN: 2667-6370
Anti-fibrotic Treatment for Pulmonary Fibrosis Induced by COVID-19: A Case Presentation
PDF
Cite
Share
Request
Case Report
VOLUME: 50 ISSUE: 3
P: 228-231
June 2022

Anti-fibrotic Treatment for Pulmonary Fibrosis Induced by COVID-19: A Case Presentation

Turk J Anaesthesiol Reanim 2022;50(3):228-231
DOI: 10.5152/TJAR.2021.20450
Bahar Sakızcı Uyar 1
Kerem Ensarioğlu 2
Bahar Kurt 2
Derya Özkan 1
Serra Özbal Güneş 3
1. Department of Anesthesiology and Reanimation, University of Health Sciences, Dışkapı Yıldırım Beyazıt Training and Research Hospital, Ankara, Turkey
2. Department of Pulmonary Medicine, University of Health Sciences, Dışkapı Yıldırım Beyazıt Training and Research Hospital, Ankara, Turkey
3. Department of Radiology, University of Health Sciences, Dışkapı Yıldırım Beyazıt Training and Research Hospital, Ankara, Turkey
No information available.
No information available
Received Date: 07.01.2021
Accepted Date: 17.03.2021
PDF
Cite
Share
Request

ABSTRACT

Coronavirus disease 19 infection clinical presentation varies from asymptomatic cases to acute respiratory distress syndromes. In some cases, pulmonary fibrosis is observed after or during the disease. Pirfenidone is an agent approved for the treatment of idiopathic pulmonary fibrosis. Here we report a patient treated with pirfenidone for pulmonary fibrosis related to coronavirus disease 19.

Keywords: Antifibrotic, COVID-19, pirfenidone, pulmonary fibrosis, respiratory distress

References

2024 ©️ Galenos Publishing House